{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.35,"timestamp":1741151520000,"preClose":0.3,"halted":0,"volume":25580,"delay":0,"changeRate":0.166667,"change":0.05,"floatShares":6241093,"shares":14143000,"eps":-0.0015,"lyrEps":-0.005504,"amount":8566,"amplitude":0.166667,"volumeRatio":0.4964483942142632,"dividePrice":0,"prevYearClose":0.4,"fiveDayClose":0.42,"twentyDayClose":0.39},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","floatShares":6241093,"roa":"--","roe":"--","lyrEps":-0.005504,"volumeRatio":0.4964483942142632,"shares":14143000,"dividePrice":0,"high":0.36,"amplitude":0.166667,"preClose":0.3,"low":0.31,"week52Low":0.004,"pbRate":"--","week52High":0.68,"institutionHeld":0,"latestPrice":0.35,"eps":-0.0015,"divideRate":0,"volume":25580,"delay":0,"ttmEps":-0.0015,"open":0.31,"prevYearClose":0.4,"prevWeekClose":0.39,"prevMonthClose":0.39,"prevQuarterClose":0.4,"fiveDayClose":0.42,"twentyDayClose":0.39,"sixtyDayClose":0.625},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMB.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-07-04","symbol":"CMB.AU","defaultRemindTime":1720051200000,"type":"split","dateTimestamp":1720015200000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMB.AU\",market:\"AU\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CMB.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514303111","title":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303111?lang=en_us&edition=fundamental","pubTime":"2025-02-25 13:09","pubTimestamp":1740460163,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial ProtocolFeb 25 (Reuters) - Cambium Bio Ltd CMB.AX:FDA APPROVES ELATE OCULAR PHASE 3 CLINICAL TRIAL PROTOCOLFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514039295","title":"Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514039295","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514039295?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:38","pubTimestamp":1740458334,"startTime":"0","endTime":"0","summary":"Cambium Bio  has received approval from the US Food and Drug Administration  for a protocol relating to Phase 3 clinical trials of its Elate Ocular treatment for moderate-to-severe dry eye disease.The approval represents a key milestone in advancing Elate Ocular towards market registration and follows the FDA granting the product fast-track designation in December.Fast-tracking helps expedite the review of drugs that treat serious conditions and address unmet medical needs.Chief executive officer Karolis Rosickas said the Phase 3 protocol was pivotal to the development of the Elate Ocular trials.“The trial design reflects extensive consultation with regulatory experts and key opinion leaders to ensure we meet FDA requirements for registration,” he said.The fast-track designation will enable Cambium to have more frequent interactions with the FDA throughout Elate Ocular’s development process and makes the product eligible for potential accelerated approvals and priority reviews.“With fa","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/cambium-bio-us-fda-approval-phase-3-elate-ocular-dry-eye-disease-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514708970","title":"Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708970","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514708970?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:37","pubTimestamp":1740443820,"startTime":"0","endTime":"0","summary":"Cambium Bio  has flagged approval from the U.S. FDA for phase three of a clinical trial using its Elate Ocular product to treat moderate to severe dry eye disease.The market clearly liked the news – Cambium jumped more than 40% in the second hour of trade; the latest winner in a small basket of biotech stocks progressing towards late-stage approvals and commercialisation.In Cambium’s own words, the Phase 3 trial represents a final step towards market registration for its Elate Ocular product, with the third trial typically being the final in the FDA’s approval ringer. The Phase 3 program is ultimately geared to acquire a Biologics Licence Application . Trial sites in both the U.S. and Australia – “and select other countries” – will constitute Phase 3; Cambium won FDA Fast Track designation for Elate last December.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cambium-jumps-43-as-fda-approves-phase-3-trial-for-elate-ocular-2025-02-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2514670775","title":"Cambium Bio Ltd -  FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670775?lang=en_us&edition=fundamental","pubTime":"2025-02-25 07:15","pubTimestamp":1740438945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14}]}}